Pertuzumab/trastuzumab in early stage HER2-positive breast cancer: 5-year and final analysis of the BERENICE trial

Dang, C.Ewer, M. S.Delaloge, S.Ferrero, J-M.Colomer, R.de la Cruz Merino, L.Dadswell, K.Verrill, M.Eiger, D.Sarkar, S.de Haas, S.Restuccia, E.Swain, S. M.2025-01-072025-01-072021-05-080923-7534https://hdl.handle.net/10668/27618enPertuzumab/trastuzumab in early stage HER2-positive breast cancer: 5-year and final analysis of the BERENICE trialconference outputopen access10.1016/j.annonc.2021.03.0571569-8041http://www.annalsofoncology.org/article/S0923753421009352/pdf648924400044